WntResearch's board and management subscribe for units in ongoing rights issue
WntResearch AB (“WntResearch” or the “Company”) today announces that parts of the Board and management subscribe for units in the ongoing rights issue of units consisting of shares and warrants (the “Rights Issue”), which was announced on February 5, 2021.
The Board of Directors and Management subscribe for units in the Rights Issue as follows:
Gudrun Anstrén, Chairman of the Board
Gudrun Anstrén subscribes for 2,639 units, corresponding to SEK 21,376.
Tommy Andersson, Board member
Tommy Andersson subscribes for 1,000 units, corresponding to SEK 8,100.
Martin Olovsson, Board member
Martin Olovsson subscribes for 2,777 units, corresponding to SEK 22,494.
Peter Ström, Board member
Peter Ström subscribes for 13,555 units, corresponding to SEK 109,796.
Jan Nilsson, Board member
Jan Nilsson subscribes for 1,235 units, corresponding to SEK 10,000.
Anders Rabbe, CEO
Anders Rabbe subscribes for 18,519 units, corresponding to SEK 150,000.
Anders Tidfors, CFO
Anders Tidfors subscribes for 2,469 units, corresponding to SEK 20,000.
Klaus Christensen, Head of Marketing
Klaus Christensen subscribes for 2,000 units, corresponding to SEK 16,200.
Above persons from the board and management subscribe for units with and without preferential rights.
Schedule for the Rights Issue
• April 19, 2021: Last day for trading in unit rights.
• April 22, 2021: Last day for subscription in the Rights Issue.
• April 27, 2021: Indicative date for publication of outcome in the Rights Issue.
Advisor
Mangold Fondkommission AB is the financial advisor and Setterwalls Advokatbyrå AB is the legal advisor to WntResearch in connection with the Rights Issue.
For further information:
Anders Rabbe, acting CEO
Phone: +46 707 646 500
E-mail: anders.rabbe@wntresearch.com
This information was submitted for publication, through the agency of the contact person set out above, on April 14, 2021.
About WntResearch
WntResearch is a biotech company in oncology that develops new therapies intended to prevent the metastatic process. The company's research is focused on studying the endogenous protein WNT5A, which in scientific studies has shown to affect tumor cells' ability to move and spread in the body. WntResearch drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is intended to reduce the mobility and spread of cancer cells thus preventing metastases from occurring. Although current cancer treatment has become more effective, there are no effective ways to prevent the onset of metastases that cause about 90 percent of all cancer-related deaths. Foxy-5 has a unique mechanism of action and has shown a good safety profile with few side effects in two Phase I clinical trials. The safety and efficacy of Foxy-5 are now being evaluated in the ongoing Phase 2 clinical trial NeoFox, in patients with stage II-III colon cancer.
WntResearch is listed on the Spotlight Stock Market. For more information, please visit: www.wntresearch.com